Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
SL Khaw, D Merino, MA Anderson, SP Glaser, P Bouillet, AW Roberts, DCS Huang
Leukemia | NATURE PUBLISHING GROUP | Published : 2014
Awarded by Australian National Health and Medical Research Council
Awarded by Independent Research Institutes Infrastructure
Awarded by Leukemia and Lymphoma Society
We thank our colleagues Andreas Strasser and Jerry Adams for helpful discussions. We thank Abbvie and Genentech for providing ABT-737, navitoclax (ABT-263) and ABT-199; Naomi Sprigg, Lisa Magee, Mary Moody, Lina Laskos and Jenni Harris for assistance with obtaining human samples; Louise Cengia, Angela Georgiou and Mikara Robati for technical assistance; Lorraine O'Reilly for antibodies; Bruno Helbert and Carley Young for mouse genotyping; and Emily Sutherland, Tania Camilleri, Anndrea Pomphrey and Giovanni Siciliano for mouse husbandry. This work was supported by fellowships and grants from the Australian National Health and Medical Research Council (Career Development Award to PB; Practitioner Fellowship to AWR; Research Fellowships to DCSH and PB; Program Grants 461219, 461221, 1051235 and 1016701; Independent Research Institutes Infrastructure Support Scheme grant 361646); the Leukemia and Lymphoma Society (SCOR grants 7417-07 and 7001-13); the Australian Research Council (Discovery Project to DM); the Leukaemia Foundation of Australia (Fellowship to SLK; Grants-in-Aid to SPG, AWR and DCSH); the Cancer Council of Victoria (Fellowship to SLK; Project Grant to AWR and DCSH); Australian Cancer Research Foundation; and a Victorian State Government Operational Infrastructure Support (OIS) Grant.